Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 105-114 , April 2008

Using Microarray Analysis as a Prognostic and Predictive Tool in Oncology: Focus on Breast Cancer and Normal Tissue Toxicity

  • Dimitry S.A. Nuyten, MD

      Affiliations

    • Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    • Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    • Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    • Corresponding Author InformationAddress reprint requests to Dimitry S.A. Nuyten, MD, Divisions of Radiation Oncology, Diagnostic Oncology, and Experimental Therapy, The Netherlands Cancer Institute, Plesmaniaan 121, 1066 CX Amsterdam, The Netherlands.
    • ,
  • Marc J. van de Vijver, MD, PhD

      Affiliations

    • Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    • Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

References 

  1. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–37
  2. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–470
  3. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996;14:457–460
  4. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–14868
  5. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116–5121
  6. Tibshirani R, Hastie T, Narasimhan B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99:6567–6572
  7. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004;2:E108
  8. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet. 2005;365:488–492
  9. Hummerich J, Werle-Schneider G, Popanda O, et al. Constitutive mRNA expression of DNA repair-related genes as a biomarker for clinical radio-resistance: A pilot study in prostate cancer patients receiving radiotherapy. Int J Radiat Biol. 2006;82:593–604
  10. Svensson JP, Stalpers LJ, Esveldt-van Lange RE, et al. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med. 2006;3:e422
  11. Vozenin-Brotons MC, Milliat F, Linard C, et al. Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res. 2004;161:299–311
  12. Harima Y, Togashi A, Horikoshi K, et al. Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004;60:237–248
  13. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  14. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002;4:295–303
  15. Helland S, Johnsen H, Froyland C, et al. Radiation-induced effects on gene expression: An in vivo study on breast cancer. Radiother Oncol. 2006;80:230–235
  16. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? (A subgroup analysis of the DBCG 82 b&c randomized trials). Radiother Oncol. 2007;82:247–253
  17. Pierce LJ. The use of radiotherapy after mastectomy: A review of the literature. J Clin Oncol. 2005;23:1706–1717
  18. Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006;24:4594–4602
  19. Kreike B, Halfwerk H, Kristel P, et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res. 2006;12:5705–5712
  20. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62
  21. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol. 2004;2:E7
  22. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47
  23. Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  24. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  25. Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002;4:R3
  26. Chang J, Wooten E, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–369
  27. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24:4236–4244
  28. Hannemann J, Oosterkamp HM, Bosch CA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005;23:3331–3342
  29. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–1300
  30. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  31. Buyse M, Loi S, van’t VL, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192
  32. MINDACT. http://www.eortc.be/services/unit/mindact/MINDACT_websiteii.aspAccessed November 29, 2007
  33. Adjuvant! Online. http://www.adjuvantonline.coAccessed
  34. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–272
  35. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–679
  36. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–1671
  37. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG Multicenter Independent Validation Series. Clin Cancer Res. 2007;13:3207–3214
  38. Desmedt C, Sotiriou C. Proliferation: The most prominent predictor of clinical outcome in breast cancer. Cell Cycle. 2006;5:2198–2202
  39. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–569
  40. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  41. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96
  42. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  43. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  44. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  45. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005;102:3738–3743
  46. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–616
  47. Perou CM, Jeffrey SS, van de RM, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999;96:9212–9217
  48. Dvorak HF. Tumors: Wounds that do not heal (Similarities between tumor stroma generation and wound healing). N Engl J Med. 1986;315:1650–1659
  49. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–447
  50. Adler AS, Lin M, Horlings H, et al. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet. 2006;38:421–430

PII: S1053-4296(07)00098-7

doi: 10.1016/j.semradonc.2007.10.007

Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 105-114 , April 2008

Article Tools

* Image Usage & Resolution